By Maryanne Demasi, PhD, Paula Byrne, PhD, Mark Jones, PhD, Robert DuBroff, MD. On several occasions, we have been asked to respond to a critique of our 2022 systematic review and meta-analysis on statin trials. The critique was written by Peter Attia in April 2022, a physician and popular podcaster whose interests lie at the intersection of longevity, lipids and heart disease.
Response to a critique of our statin analysis
By Maryanne Demasi, PhD, Paula Byrne, PhD, Mark Jones, PhD, Robert DuBroff, MD. On several occasions, we have been asked to respond to a critique of our 2022 systematic review and meta-analysis on statin trials. The critique was written by Peter Attia in April 2022, a physician and popular podcaster whose interests lie at the intersection of longevity, lipids and heart disease.